COVID-19: dealing with a potential risk factor for chronic neurological disorders.
Tommaso SchirinziFrancesca BovisClaudio LiguoriPublished in: Journal of neurology (2020)
SARS-CoV2 infection is responsible for a complex clinical syndrome, named Coronavirus Disease 2019 (COVID-19), whose main consequences are severe pneumonia and acute respiratory distress syndrome. Occurrence of acute and subacute neurological manifestations (encephalitis, stroke, headache, seizures, Guillain-Barrè syndrome) is increasingly reported in patients with COVID-19. Moreover, SARS-CoV2 immunopathology and tissue colonization in the gut and the central nervous system, and the systemic inflammatory response during COVID-19 may potentially trigger chronic autoimmune and neurodegenerative disorders. Specifically, Parkinson's disease, multiple sclerosis and narcolepsy present several pathogenic mechanisms that can be hypothetically initiated by SARS-CoV2 infection in susceptible individuals. In this short narrative review, we summarize the clinical evidence supporting the rationale for investigating SARS-CoV2 infection as risk factor for these neurological disorders, and suggest the opportunity to perform in the future SARS-CoV2 serology when diagnosing these disorders.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- acute respiratory distress syndrome
- multiple sclerosis
- inflammatory response
- drug induced
- extracorporeal membrane oxygenation
- risk assessment
- mechanical ventilation
- cerebral ischemia
- liver failure
- clinical trial
- respiratory failure
- current status
- immune response
- intensive care unit
- aortic dissection
- toll like receptor
- human health
- lps induced